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Abstract Dose–response curves for headaches relief and
adverse events (AEs) are presented for ﬁve triptans: suma-
triptan, zolmitriptan, naratriptan, almotriptan, and frova-
triptan,andtheCGRPantagonisttelcagepant.Theupperpart
of the efﬁcacy curve of the triptans is generally ﬂat, the so-
called ceiling effect; and none of the oral triptans, even in
high doses, are as effective as subcutaneous sumatriptan, In
contrast, AEs increases with increasing dose without a ceil-
ing effect. The optimal dose for the triptans is mainly
determined by tolerability. Telcagepant has an excellent
tolerability and can be used in migraine patients with car-
diovascularco-morbidity.Basedontheliteraturethetriptans
and telcagepant are rated in a table for efﬁcacy and
tolerability.
Keywords Migraine  Acute treatment  Triptans 
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We conclude that a single 6 mg dose of sumatriptan given
subcutaneously is a highly effective, rapid-acting, and well-
tolerated treatment for migraine attacks. [1]
Introduction
The vignette suggests that ‘‘the philosophers’s stone’’ has
been found with the introduction of sumatriptan.
Subcutaneous sumatriptan 6 mg and subcutaneous nara-
triptan 10 mg are both highly effective drugs. Headache
relief at 2 h was 81, 85–89% [1–4], and 91% [2],
respectively; but in both cases there is a high incidence
of adverse events (AEs) (53–71, 85% [2, 3]). Most of
these AEs after subcutaneous sumatriptan were reported
as being minor and transient in one study [1] whereas in
another simultaneously conducted study 20% of the AEs
after sumatriptan and 17% after placebo were described
as severe [2].
In clinical practice with oral triptans not all migraine
patients respond to a triptan and AEs can be a problem. The
optimal balance of efﬁcacy and tolerability depends on the
combined dose–response curves for both antimigraine
effect and incidence of AEs. These dose–response curves
for oral triptans will be reviewed, the ﬁndings discussed
and ﬁnally my clinical comments will be presented.
Methods and results
Dose-deﬁning, randomised, controlled trials (RCTs) of
triptans were searched for in PubMed and in The Head-
aches [5]. Studies deﬁning the dose–response curves of
oral triptans for both efﬁcacy and the incidence of AE
were selected for analysis. In addition, large dose-deﬁning
studies on the CGRP antagonist telcegepant were searched
for.
For three triptans (zolmitriptan, naratriptan, and almo-
triptan) the balance of efﬁcacy and tolerability could be
evaluated by drawing the curves from one dose-deﬁning
study as shown in Figs. 2, 3, and 4. Two dose-deﬁning
studies [5, 6] were needed to evaluate the full dose–
responses curves for sumatriptan and frovatriptan (Figs. 1,
2, and 6). For rizatriptan and eletriptan the incidence of
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DOI 10.1007/s10194-011-0309-5AEs was not presented [7–11] and only the results for
efﬁcacy of these two triptans are mentioned brieﬂy.
Sumatriptan is the ﬁrst and standard triptan and it took
two studies, from 1991 and 1998, before the dose–response
curve for oral sumatriptan could be established (Figs. 1, 2)
[6, 12]. It is evident from Figs. 1 and 2 that there is an
upper ﬂat part of the dose–response curve for efﬁcacy,
starting at sumatriptan 50 mg, and there is no increase
in efﬁcacy up to the 300 mg dose. The incidence of AEs
increases with increasing dose of sumatriptan, reaching a
maximum of 53% after 300 mg sumatriptan. 25 mg suma-
triptan was the minimum effective dose [6]. For sumatriptan
50 mg there was 7% more AEs than after placebo (Fig. 1a)
which is quite similar to the 9% found in one meta-analysis
[13]. The recommended starting dose of oral sumatriptan is
50 mg. This choice is based on maximal efﬁcacy and rea-
sonable tolerability (Figs. 1, 2).
The dose–response curves for zolmitriptan are shown in
Fig. 3 [14]. Again there is a ﬂat upper part for efﬁcacy. The
starting dose for this plateau is 2.5 mg zolmitriptan. The
AEs increase with increasing dose and reach a maximum of
67% after 10 mg zolmitriptan. For zolmitriptan 2.5 mg
there were 14% more AEs than after placebo. This inci-
dence is quite similar to the 15% found in a meta-analysis
[13]. The biggest difference between efﬁcacy and AEs
(Fig. 2) was observed at the 2.5 mg dose which is therefore
the recommended dose for zolmitriptan [15].
Oral naratriptan apparently has a dose–response curve
for efﬁcacy [16] with a plateau which starts at 7.5 mg
(Fig. 4). For AEs there is a similar plateau in this dose
range. At 2.5 mg there are no more AEs than with placebo,
as has also been observed in a meta-analysis [13]. The
2.5 mg dose of naratriptan was subsequently chosen as a
recommended dose without any more AEs than placebo,
the so-called ‘‘gentle triptan’’ [17].
The dose–response curves for almotriptan are shown in
Fig. 5 [18] and there is a slight increase in efﬁcacy from
6.25 (56%) to 25 mg (66%). The incidences of AEs are
remarkably low and ﬁrst at 25 mg there is a slight increase
compared with placebo. The AEs up to 12.5 mg (16–18%)
were described as being mild in the majority of patients
whereas the AEs after 25 mg (25%) were described as
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Fig. 1 Effect of sumatriptan 25, 50, and 100 mg on headache relief
and adverse events in one RCT [6]
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Fig. 2 Effect of sumatriptan 100, 200, and 300 mg on headache
relief and adverse events in one RCT [7]
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Fig. 3 Effect of zolmitriptan 1, 2.5, 5, and 10 mg on headache relief
and adverse events in one RCT [14]
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Fig. 4 Effect of naratriptan 1, 2.5, 5, 7.5, and 10 mg on headache
relief and adverse events in one RCT [16]
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123being of moderate intensity in 48% of cases. Also in a
meta-analysis almotriptan 12.5 mg was found to have AEs
at the placebo level [13]. Mostly based on the change in
intensity of AEs almotriptan 12.5 mg was chosen as the
recommended dose [15, 18].
The efﬁcacy of frovatriptan was evaluated by pooling
the results of two RCTs [19]. The combined results are
shown in Fig. 6. From 2.5 mg and with higher doses there
is a ﬂat dose–response curve. Below 2.5 mg there is no
efﬁcacy. The incidences of AEs increase with dose and
there is a maximum of 72% at 40 mg. The recommended
dose is frovatriptan 2.5 mg, the lowest dose with efﬁcacy.
For rizatriptan and eletriptan the total incidences of AEs
(any patients with an AE) are not reported but the inci-
dences of individual AEs are given in tables [8–11]. Thus
only the dose–response curves for efﬁcacy of these two
triptans can be evaluated. In one dose-ﬁnding RCT
(n = 417) headache relief was 18% with placebo, and 21,
45, and 48%, with rizatriptan doses of 2.5, 5, and 10 mg,
respectively [10]. In a RCT (n = 449) exploring the upper
part of the dose–response curve for rizatriptan headache
relief was 18% with placebo and 52, 56, and 67% with 10,
20, and 40 mg doses of rizatriptan. AEs occurred more
frequently after a 40 mg dose of rizatriptan [11]. In one
RCT (n = 1,190) investigating the effect of eletriptan
headache relief was 20% with placebo an 47, 62, and 59%
with 20, 40, and 80 mg doses of eletriptan [9] and in
another RCT (n = 1334) [8] headache relief was 22% with
placebo and 47, 62, and 59% with the eletriptan doses of
20, 40, and 80 mg, respectively. In both RCTs AEs were
comparable for eletriptan 20 mg and placebo [8, 9]. AEs
from different trial programmes are difﬁcult to compare
because of differences in the methodology of collecting
AEs. In a meta-analyses any AE (placebo-subtracted) were
7 and 13% after 5 and 10 mg doses of rizatriptan; and 2, 6,
and 18% after 20, 40, and 80 mg, respectively, doses of
eletriptan [13]. There is thus also for these two triptans an
increase in the incidence of AEs with increase in doses.
Telcagepant, a calcitonin gene-related peptide (CGRP)
receptor antagonist, is currently being developed for the
acute treatment of migraine. In one small dose-deﬁning
RCT [20] doses of 300 and 600 mg telcagepant were found
comparable and the 300 mg dose was selected for further
investigation. The dose–response curves for telcagepant in
doses from 50 to 300 mg are shown in Fig. 7 [21]. The
incidence of AEs is at the placebo level, conﬁrming the
lack of CGRP antagonists on human vasculature [22], and
there is probably a plateau for efﬁcacy from 150 or 300 mg
and further up [21, 23]. The recommended dose will
probably be 300 mg telcagepant, a dose with maximum
effect and AEs on placebo level.
Discussion
In 2002, it was stated that triptans have served as the foot
soldiers or the advances in migraine research during the
latter part of the twentieth century [24]. How effective are
these revolutionary drugs then in clinical practice?
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Fig. 5 Effect of almotriptan 2, 6.25, 12.5, and 25 mg on headache
relief and adverse events in one RCT [18]
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Fig. 6 Effect of frovatriptan 0.5, 1, 2.5, 5, 10, 20, and 40 mg on
headache relief and adverse events in two RCTs [19]
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Fig. 7 Effect of telcagepant 50, 150, and 300 mg on headache relief
and adverse events in one RCT [21]
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123The triptans are per se highly effective drugs confer the
85–91% headache relief at 2 h after subcutaneous suma-
triptan and naratriptan [1–3]. Theoretically, it should be
possible by increasing the oral dose of a triptan to obtain
similar high response rates. This is, however, not the case.
Even with similar plasma concentrations of the sumatriptan
and naratriptan after oral and subcutaneous administration
the injection is still superior to the oral form [4]. As shown
in Figs. 1, 2, 3, and 5 there is for several triptans, suma-
triptan, zolmitriptan, and frovatriptan, a ﬂat upper part of
the dose–response curves. In addition, the efﬁcacy even
with very high doses, e.g., the 40 mg dose of frovatriptan.
(42%) and of rizatriptan (67%), is not near the efﬁcacy of
the subcutaneous form, vide supra. This higher efﬁcacy of
injected triptans compared with the oral form is most likely
due to a quicker rise in blood concentrations after subcu-
taneous injections [4].
The upper part of the dose–effect curves for several trip-
tans, sumatriptan, zolmitriptan, and frovatriptan (Figs. 1, 2,
3, and 6) demonstrate a ceiling effect for response on
migraine pain. This ceiling effect is especially pronounced
for frovatriptan for which a 16-fold increase to 40 mg from
the 2.5 mg dose did not result in an increase in efﬁcacy (see
Fig. 6). In contrast the dose–response curves for AEs show
that the incidence of AEs increases with increasing doses
(Figs. 1, 2, 3, 4, 5, and 6), and there is no indications of a
ceiling effect.
Only reporting the incidence of AEs does not in all cases
give the full picture of the clinical impact of the AEs. Thus
for almotriptan 12.5 mg AEs were reported as mild
whereas for 25 mg they were reported as moderate [18].
The global impact of AEs should be measured on suitable
quality of life scales in the future [25].
Compared to the traditionally used drug, ergotamine,
which in addition to its 5-HT1B/1D has agonistic effect on
e.g., the dopamine D2 receptor [26], the triptans act
selectively on the 5-HT1B/1D receptor [15, 27] and should
thus have a better tolerability proﬁle than ergotamine. Thus
in one RCT rectal ergotamine 2 mg (73%) was slightly
superior to rectal sumatriptan 25 mg (63%) for headache
relief but caused signiﬁcantly more nausea and/or vomit-
ing: 28 and 7%, respectively [15, 28].
Even if just recording the incidence of AEs in the bal-
ance between efﬁcacy and tolerability is not the ideal
measure of tolerability it is fair measure for the potential
for AEs of a triptan in the migraine population and in
several cases the incidence of AEs has determined the
recommended doses of the triptans. The recommended
doses are in most cases a realistic compromise between
efﬁcacy and tolerability.
The new CGRP antagonist telcagepant has an excellent
tolerability with AEs on the placebo level (see Fig. 6 [21,
23]). Telcagepant has a headache relief of 56% and has a
26% pain-free response [29] which is lower than 40% for
rizatriptan 10 mg [13].
Clinical comments
My personal rating of the triptans and telcagepant is given
in Table 1. It is based both on comparative RCTs [5], two
systematic reviews [27, 30], and a meta-analysis [13]. For
efﬁcacy ? is given for a drug somewhat better than pla-
cebo, ?? is given for an effective drug, and ??? for a
highly effective drug. For tolerability 0 is given for no
more AES than placebo, ? for \10% more AEs than
placebo, ?? for\25% more AEs than placebo, and ???
for[25% more AEs than placebo.
It should be noted that there are most likely inter-indi-
vidual difference to responses to triptans. Thus one patient
A may use one triptan successfully whereas patient B may
prefer another triptan. This variability among triptans is
most likely due to both a pharmacokinetic and pharmaco-
dynamic variability among the drugs [31]. From a phar-
macokinetic point of view almotriptan has the advantage of
a high oral bioavailability of 80% and is more unlikely to
Table 1 Efﬁcacy and
tolerability of triptans and
telcagepant
For explanation of (? to ???)
for efﬁcacy and of (0 to ???)
for AES potential, see text. The
rating is based on [13, 15, 21,
23, 27, 30]
Drug and dose
(mg)
Efﬁcacy
(?, ??, and ???)
Adverse events potential
(0, ?, ??, and ???)
Subcutaneous sumatriptan: 6 ??? ???
Sumatriptan: 50 ?? ?
Sumatriptan: 100 ?? ??
Naratriptan: 2.5 ? 0
Rizatriptan: 10 ?? ??
Zolmitriptan: 2.5 ?? ??
Eletriptan: 40 ?? ??
Almotriptan: 12.5 ?? 0
Frovatriptan: 2.5 ??
Telcagepant: 300 ?? 0
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123vary among subjects than e.g., sumatriptan with an oral
bioavailability of 14% [15, 27]. Because of no more AEs in
RCTs than placebo (see Fig. 5) almotriptan 12.5 mg can
apparently (see Table 1) be a ﬁrst choice triptan if no AEs
are tolerated. It should be noted, however, that some
patients can experience so-called ‘‘triptan’’ symptoms (see
below) even after almotriptan as after other triptans.
Sumatriptan is now of patent in most countries and
sumatriptan 50–100 mg should therefore in clinical prac-
tice be the triptan of ﬁrst choice when triptans are used de
novo in migraine patients.
Even if the AEs after triptans are in most cases mild to
moderate and transient they can be frightening for the
patients which should be informed about possible AEs.
Somnolence and asthenia are reported as AEs of triptan but
they are most likely partly treatment-emergent CNS symp-
toms of the migraine attack following the treatment with
triptans [26].Even so they are experienced by the patientsas
bothersome AEs. The so-called ‘‘triptans’’ symptoms [32]
are shown for placebo and 2.5 mg recommended dose of
zolmiriptan in Table 2 [15, 33]. Note that zolmitriptan
2.5 mgcaused17%moreadverseeventsthanplacebo.Chest
symptoms (mainly tightness and pressure) have been
reported to occur in up to 20% (tablets) and 40% (subcuta-
neous injection) of the patients treated with sumatriptan
some time [15, 34]. Such symptoms can be a frightening
experience for the patients, and they should be warned in
advance of the risk of the symptoms and should be informed
about the transient and generally benign nature.
If telcagepant becomes available it will be the drug of
ﬁrst choice for the patients with migraine and cardiovas-
cular diseases or high risk for such diseases. It will also be
a good choice if the migraine patient has intolerable AEs
when treating with triptans.
It should be noted that with any drug used in acute
migraine treatment there is a different balance of efﬁcacy
and tolerability in the individual patient and there is thus no
standard dose that suites every patient. In addition, some
patients may prefer a very effective drug with some AEs to
a drug with lower efﬁcacy and virtually no AEs. Drugs and
doses should thus be tailored to the need of the individual
patient.
Finally, it is important to note that the majority of the
patients experience no AEs with use of the oral speciﬁc
5HT1B/1D receptor agonists, the triptans, in the recom-
mended doses (see, Fig 1, 2, 3, 4, and 5).
When AEs occur they are in most cases mild to mod-
erate and transient. On balance, the triptans with their
proven efﬁcacy and an acceptable tolerability proﬁle have
been a major step forward in the acute treatment of
migraine.
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